BG Medicine (BGMD) Stock Price, News & Analysis

Company Overview

BG Medicine, Inc., headquartered in Waltham, Massachusetts, is a clinical diagnostics company specializing in proprietary biomarker assays for the diagnosis and management of cardiovascular and renal diseases. The company’s flagship product is a B-type natriuretic peptide (BNP) test, offered both as a laboratory-developed test in its CLIA-certified facility and as reagent kits compatible with major immunoassay analyzers. This test aids clinicians in assessing heart failure severity and guiding patient treatment decisions.

Founded in the early 2000s, BG Medicine has established partnerships with hospital and reference laboratories across North America and select international markets. Beyond its BNP assay, the company has invested in the development of additional peptide-based immunoassays, working toward a multi-marker approach for more comprehensive cardiovascular risk evaluation and disease management.

Led by a management team with deep experience in diagnostic development and commercialization, BG Medicine continues to focus its research and development efforts on expanding its test portfolio. By collaborating with instrument manufacturers and clinical laboratories, the company aims to deliver precision diagnostic tools that support personalized care strategies for patients with chronic heart and kidney conditions.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 11/17/2015
• Today: 8/31/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: OTCMKTS:BGMD
• Previous Symbol: NASDAQ:BGMD
• CIK: 1407038
• Web: www.bg-medicine.com
• Phone: (508) 549-5710
• Fax: 781-895-1119
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 0.93